Heterogeneous nuclear ribonucleoprotein A3 pseudogene 16 (HNRNPA3P16)

Heterogeneous nuclear ribonucleoprotein A3 pseudogene 16 (HNRNPA3P16) is classified as a **pseudogene** of the HNRNPA3 gene, meaning it is a genomic DNA sequence similar to HNRNPA3 but is generally considered non-functional and does not produce a functional protein[3][5]. The HNRNPA3 gene, in contrast, encodes a member of the heterogeneous nuclear ribonucleoproteins (hnRNPs), which are RNA binding proteins involved in mRNA splicing and regulation and are implicated in cancer biology[1][2]. However, pseudogenes like HNRNPA3P16 typically lack biological activity, are not therapeutic targets, and have no established roles in disease, function, drug interaction, or patient biomarker profiles. There is no evidence that HNRNPA3P16 is a therapeutic target or has any known relevance in health or disease beyond its status as a pseudogene. **Clarification:** HNRNPA3P16 refers to a pseudogene and not to the functional protein HNRNPA3. Structured biological, pharmacological, or clinical data (such as function, target class, or therapeutic use) do not exist for pseudogenes unless specifically reported, and there is no evidence suggesting HNRNPA3P16 has functional significance[3][5].

Other names

HNRNPA3P16